This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Karow A, Nienhold R, Lundberg P, Peroni E, Putti MC, Randi ML, et al. Mutational profile of childhood myeloproliferative neoplasms. Leukemia. 2015;29:2407–9.
Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22:1557–66.
Giona F, Teofili L, Moleti ML, Martini M, Palumbo G, Amendola A, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119:2219–27.
Bennett M, Stroncek DF. Recent advances in the bcr-abl negative chronic myeloproliferative diseases. J Transl Med. 2006;4:41.
Santopietro M, Palumbo G, Moleti ML, Cardarelli L, Rizzo L, Malaspina F, et al. WHO 2016 classification in 80 children and adolescents with chronic myeloproliferative neoplasms. HemaSphere. 2018;2:262–3.
Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant- positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198–200.
Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009;114:3325–8.
Leroy E, Defour JP, Sato T, Dass S, Gryshkova V, Shwe MM, et al. His499 regulates dimerization and prevents oncogenic activation by asparagine mutations of the human thrombopoietin receptor. J Biol Chem. 2016;291:2974–87.
Defour JP, Chachoua I, Pecquet C, Constantinescu SN. Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia. 2016;30:1214–6.
Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007;25:1048–53.
Acknowledgements
Expert technical support from Lidvine Genet and Céline Mouton is acknowledged. G.L. is supported by a fellowship from the Foundation “Les avions de Sébastien”, Belgium. Research support to SNC was from Ludwig Cancer Research, WELBIO, Fondation contre le cancer, Salus Sanguini, FRS-FNRS Belgium and project ARC10/15-027.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Defour, JP., Levy, G., Leroy, E. et al. The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters. Leukemia 33, 563–564 (2019). https://doi.org/10.1038/s41375-018-0356-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0356-x